with human multiple myeloma cancer cells to form myeloma tumors in
their flanks. Treated mice were injected intratumorally with Factor 5A
therapy encapsulated in nanoparticles, while control mice received a
nanoparticle without the Factor 5A therapy. One of the dosing regimens
showed evidence of significant tumor regression relative to the
untreated control mice, while the other showed a diminished rate of
tumor growth along with some regression.
"As our recent accomplishments indicate, we continue to execute on our
strategy," said Bruce Galton, President and CEO of Senesco. We believe we
have advanced our human health preclinical research program via the
selection of a CRO and the successful completion of certain in-vivo
preclinical studies in multiple myeloma. Our objectives for the remainder
of the year are to continue to evaluate dosing regimens and encapsulation
vehicles in preclinical multiple myeloma cancer models, to identify
contract manufacturing centers to produce cGMP materials, to plan and carry
out the necessary toxicology studies, and to work with our CRO to begin
preparation of an Investigational New Drug Application."
-- Revenue of $6,250 for the three month period ended December 31, 2007
consisted of the amortized portion of previous milestone payments
received in connection with certain license agreements. During the
three-month period ended December 31, 2006, revenue of $181,250
consisted of initial fees, milestone payments and the amortized portion
of previous milestone payments received in connection with certain
development and license agreements.
-- Research and development expenses during the three month period ended
December 31, 2007 were $392,254, compared with $239,395 during the
three month period ended December 31, 2006. This increase resulted
from an incre
|SOURCE Senesco Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved